CLSI H21™
Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays

CLSI H21 provides procedures for collecting, transporting, and storing blood, processing blood specimens, storing plasma for coagulation testing, and general recommendations for performing the tests.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays

Anne M. Winkler, MD
Laura A. Worfolk, PhD, MS, MLS(ASCP)
Donna Castellone, MS, MASCPE, MLS(ASCP), SH
Marc D. Goldford, BS
Daniel Hesselgesser, MLS(ASCP)
Jeffrey S. Jhang, MD
Sharon Verg Johnson MBA, DLM(ASCP), CLT(State of NY), MLT
Kandice Kottke-Marchant, MD, PhD
Kevin J. McGlinchey, MLS(ASCP), CLs(CG)
Joern Meuer, PhD
Jeb Monasterial, MLS

Heddie L. Nichols, PhD, PHM
Malissa S. Norfolk, MLS(ASCP)CM, SHCM
Paul W. Riley, PhD, MBA
Renee Rosa, BS, MT, H(ASCP)
Sara P. Serna, DCLS, MLS(ASCP)CM
Elona Turley, MD, FRCPC
Elizabeth M. Van Cott, MD
Nicholas Vanderslice, PhD
Oksana Volod, MD
Katherine Whelchel, MLS(ASCP)SH

Abstract

Clinical and Laboratory Standards Institute H21—Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays provides procedures for the collection, transport, and processing of blood specimens for plasma-based coagulation testing. Samples referred for coagulation testing are susceptible to preexamination errors, including those resulting from specimen collection and mixing, storage and transportation, various patient factors, and exogenous interferences. Thus, attention to these errors is important. CLSI H21 is primarily for laboratory and/or clinical personnel responsible for performing and interpreting plasma-based coagulation assays.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100  F: +1.610.688.0700  E: customerservice@clsi.org  W: www.clsi.org
## Contents

Abstract ................................................................. i
Committee Membership ........................................ iii
Foreword ................................................................. vii

### Chapter 1: Introduction
1.1 Scope ........................................................................ 2
1.2 Background .................................................................. 2
1.3 Standard Precautions .................................................. 2
1.4 Terminology .............................................................. 3

### Chapter 2: Process Work Flow and Precollection Considerations
2.1 Process Flow Chart ..................................................... 8
2.2 Test Ordering ............................................................ 9
2.3 Preexamination Patient Factors ..................................... 9

### Chapter 3: Specimen Collection
3.1 Patient Identification .................................................. 12
3.2 Methods for Obtaining Specimens ................................ 12
3.3 Specimen Collection Containers and Additives ............. 14
3.4 Specimen Collection and Mixing .................................. 15
3.5 Specimen Labeling .................................................... 16

### Chapter 4: Whole Blood Specimen Transport Before Processing
4.1 Transporting Specimens by Pneumatic Tube .................. 19
4.2 Courier Transport (Controlled Environment) ................. 20

### Chapter 5: Receipt, Processing, and Evaluation of Whole Blood Specimens
5.1 Receipt and Inspection of Specimens at Department or Instrument .................................. 22
5.2 Centrifugation ............................................................ 22
5.3 Aliquotting and Freezing Samples ............................... 23
5.4 Preexamination Issues and Interferences ....................... 23

### Chapter 6: Short-Term Storage and Stability of Centrifuged Whole Blood Specimens for Coagulation Testing

### Chapter 7: Frozen Plasma Sample Stability and Handling
7.1 Long-Term Frozen Stability in Freezer ......................... 32
7.2 Processing Frozen Samples ........................................ 33
7.3 Repeat Freeze-Thaw Cycles ...................................... 33
7.4 Transport Considerations for Frozen Samples ................ 34
## Contents (Continued)

### Chapter 8: Unacceptable Specimens
- 8.1 Summary of Causes for Specimen Rejection ........................................... 36
- 8.2 Troubleshooting Preexamination Issues ................................................... 36

### Chapter 9: Quality Systems Essentials: Considerations for the Collection and Handling of Coagulation Specimens
- 9.1 Process Focused Preexamination Testing .................................................. 40
- 9.2 Quality Monitors for Coagulation Testing ................................................ 41
- 9.3 Nonconforming Events ........................................................................... 42
- 9.4 Assessments .......................................................................................... 43

### Chapter 10: Conclusion ........................................................................... 45

### Chapter 11: Supplemental Information .................................................... 47
- References ................................................................................................. 48
- Additional Resource ................................................................................... 63
- Appendix A. Commonly Misordered Coagulation Tests ............................... 64
- Appendix B. Nomogram for the Adjustment of Sodium Citrate for Patients With Elevated Hematocrit ................................................................. 66
- Appendix C. Effects of Anticoagulants on Routine and Specialty Coagulation Assays .................................................. 67
- Appendix D. Stability of Plasma Samples for Coagulation Testing ............... 70
- The Quality Management System Approach .............................................. 74
Foreword

Highly sophisticated testing technology cannot produce good results from poorly collected specimens. CLSI H21 should enhance the uniformity of sample collection, preparation, and handling and thereby reduce many of the preexamination variables that can lead to inconsistent and erroneous coagulation test results.

Overview of Changes

This guideline replaces CLSI H21-A5, published in 2008. Several changes were made to this edition. One of the most prominent changes involved reorganizing the content into a process with multiple procedures, which is consistent with CLSI instilling QMS principles into its documents. CLSI H21 articulates a sequence of chronological procedures that comprise the process of successful collection, transport, and processing of human specimens for plasma-based coagulation testing. The quality system essentials (QSEs) are foundational building blocks that function effectively to support the laboratory’s path of workflow. Although not all aspects of the QSEs may be mandatory, adherence to the QSEs ensures that the specimen collection, transport, and processing for plasma-based coagulation testing is performed at a higher level of overall quality.

Other changes include:

- Removing guidelines for molecular hemostasis assays
- Adding a discussion of preexamination patient factors that may affect coagulation tests (Subchapter 2.3)
- Adding a list of specimen collection issues of particular relevance to plasma-based coagulation testing (Subchapter 3.2)
- Adding a discussion of unconventional samples sent for coagulation testing (Subchapter 3.2.2)
- Removing the recommendation for 129 mmol/L, 3.8% dehydrate form of trisodium citrate
- Adding recommendations for the stability of whole blood samples when stored at room temperature (Chapter 4)
- Adding a discussion of sample preexamination issues (e.g., hemolysis, icterus, lipemia) and interferences (e.g., anticoagulants, coagulation factor concentrates) (Subchapter 5.4)
- Updating the recommendation for the stability of fresh and frozen plasma samples (Chapters 6 and 7)
- Updating the list of specimen rejection criteria (Chapter 8)
- Adding a discussion on troubleshooting preexamination issues (Subchapter 8.2)
- Updating references
- Adding Appendix A for commonly misordered coagulation tests

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS

- activated partial thromboplastin time
- anticoagulant
- citrate
- coagulation
- interfering substance
- preexamination variables
- prothrombin time
- sample storage
- specimen collection
- specimen transport
Chapter 1
Introduction

Sample
Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays

Introduction

1.1 Scope

CLSI H21 discusses procedures for the collection, transport, and processing of human specimens for plasma-based coagulation testing. The intended audience includes laboratory and clinical personnel responsible for performing and interpreting plasma-based coagulation testing and manufacturers of products involved in specimen collection, storage, and preparation, as well as testing of plasma-based coagulation assays.

CLSI H21 does not cover whole blood coagulation assays, platelet function tests, thrombin generation assays, point-of-care coagulation testing, or molecular coagulation assays. CLSI H21 also does not provide general guidelines for performing coagulation testing. Guidelines for performing specific coagulation assays are provided in other CLSI documents that cover prothrombin time (PT) and activated partial thromboplastin time (APTT) assays (CLSI H47),\(^1\) factor activity assays (CLSI H48), fibrinogen assays (CLSI H50), D-dimer assays (CLSI H59), lupus anticoagulant (LA) assays (CLSI H60), and point-of-care coagulation testing (CLSI POCT14).

1.2 Background

A procedural guideline for the collection, transport, and processing of specimens for plasma-based coagulation is necessary because many preexamination variables can affect test results (eg, concentration and volume of anticoagulant or additive and specimen and sample storage time and temperature). Additionally, important diagnostic and therapeutic decisions are based on the results of coagulation assays. Most laboratory errors occur in the preexamination phase, which includes specimen collection, collection container composition and anticoagulant, tube fill volume and mixing, sample transport and processing, and routine and frozen specimen storage. Samples sent for coagulation testing are especially susceptible to preexamination variables.

1.3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.\(^8\) For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI M29.\(^9\)
2 Process Work Flow and Precollection Considerations

2.1 Process Flow Chart

Figure 1 outlines preexamination steps for a sample referred for coagulation testing. Short-term specimen storage and long-term specimen storage refer to samples that will be tested within 4 hours or greater than 4 hours of collection, respectively.

*Five basic symbols are used in this process flow chart: oval (signifies the beginning or end of a process), arrow (connects process activities), box (designates process activities), diamond (includes a question with alternative “Yes” and “No” responses), pentagon (signifies another process).

**Figure 1. Preexamination Path of Workflow**